Martin Shkreli Reacts to Sellas Life Sciences’ Positive Cancer Trial: “This Is Fake Data”
Martin Shkreli Reacts to Sellas Life Sciences’ Positive Cancer Trial: “This Is Fake Data”
YouTube26 min 52 sec
Watch on YouTube
Note: AI-generated summary based on third-party content. Not financial advice. Read more.
Quick Insights
  • Treat SLS as a high-risk, event-driven trade: its reported 24 vs. 14.7-month median survival and p=0.035 are disputed, and the share price has been extremely volatile; wait for full trial data and the prespecified statistical plan before acting.
  • The discussion provides no verified price targets or timeframes for RVMD, MRNA, CAPR, SAVA, or IONQ, so it does not support an actionable trade in those stocks.
Detailed Analysis

Sellas Life Sciences (SLS)

  • The discussion focused on Sellas’s Phase 3 REGAL trial of galinpepimut-S (GPS) as maintenance therapy for certain patients with acute myeloid leukemia (AML).
  • The company’s reported results, as quoted in the transcript, included:
    • Median overall survival of 24 months with GPS versus 14.7 months for the comparison group.
    • A hazard ratio of 0.59, described in the release as a 41% reduction in the risk of death.
    • A reported p-value of 0.035 and a claim that the trial met its primary endpoint.
  • Host Martin Shkreli was strongly bearish, calling the data fake and questioning whether it was reliable. His concerns included the trial being unblinded/open-label, the lack of a Kaplan–Meier survival curve in the material he reviewed, possible effects of censored patients, and whether the analysis followed the intent-to-treat population.
  • He also argued that interim alpha spending could affect whether the result meets the relevant statistical threshold. The transcript does not provide the full statistical plan needed to assess that claim.
  • The stock was described as around $22, after being near $30 earlier in the day, and later trading below $20. The host also referred to volatility-related trading halts.

Takeaways

  • Treat the reported trial result and the host’s accusations as competing claims, not as a settled conclusion. A p-value of 0.035 is below 0.05, but the correct significance threshold depends on the prespecified trial design and any interim-testing adjustments.
  • Before forming a view on SLS, look for the complete trial data, including the survival curves, patient population and analysis method, censoring details, and the prespecified statistical plan.
  • The sharp price moves and disputed interpretation point to substantial event-driven risk. The transcript offers no independently verified price target or investment recommendation.

Revolution Medicines (RVMD)

  • Shkreli cited Revolution Medicines’ RAS-targeting cancer drug, which he referred to as “Razon-Q,” as an example of what he considered convincing clinical data.
  • He praised its Kaplan–Meier curve and said the drug’s mechanism made sense for RAS-driven cancers. He described it as one of the best drugs ever, indicating a strongly bullish view, but provided no valuation, price target, or timeline.

Takeaways

  • The comments reflect the host’s favorable view of the company’s clinical evidence and drug mechanism, not a full investment analysis.
  • Investors would need to assess the specific drug, trial results, and company valuation separately; the transcript supplies no detailed figures for doing so.

Moderna (MRNA)

  • Shkreli briefly said he had made money on Moderna. He did not discuss the company’s business, prospects, or a current investment view.

Takeaways

  • This is only a reference to a past trade, not a stated bullish or bearish thesis or a recommendation.

Capricor Therapeutics (CAPR)

  • The transcript refers to “Capricorn” and “Capricor,” including a sarcastic reference to being treated with “Capricor IV.” Shkreli grouped the company with businesses he accused of misleading investors.
  • No supporting detail about Capricor’s clinical data, financials, or products was provided in the discussion.

Takeaways

  • The negative characterization is the host’s opinion and is not substantiated in the transcript. It is not enough on its own to assess CAPR.

Cassava Sciences (SAVA)

  • Shkreli cited Cassava as another company he characterized as a scam. The transcript also mentions simufilam, which he mockingly presented as a drug that would be used in an imaginary hospital scenario.
  • No new clinical or financial information about Cassava was discussed.

Takeaways

  • The comments express a strongly bearish opinion, but the transcript provides no evidence with which to evaluate the accusation or form an independent view on SAVA.

IonQ (IONQ)

  • Shkreli made a brief, dismissive comparison to IonQ while criticizing companies he viewed as promotional or fraudulent. He gave no specifics about IonQ’s business or evidence for the accusation.

Takeaways

  • Treat this as an offhand negative remark rather than a developed investment thesis. The transcript does not support a substantive assessment of IONQ.

Small-Cap Biotech and Clinical-Trial Data

  • A central theme was the risk of investing in companies whose share prices respond sharply to trial announcements, especially when the full statistical details are not yet available.
  • The host emphasized possible issues such as open-label trial design, interim statistical adjustments, censoring, and whether reported analyses include all intended patients. These were raised as concerns about the REGAL results, not established findings about the trial.

Takeaways

  • For clinical-trial-driven stocks, review the full results and prespecified analysis plan rather than relying on a press-release headline or a commentator’s interpretation.
  • Distinguish a company’s reported endpoint and statistical result from questions about how robust the result is and whether it may support regulatory approval.
Ask about this postAnswers are grounded in this post's content.
Video Description
Sign Up For Godel Terminal: https://app.godelterminal.com/?via=shkreliplanet Use Promo Code: Shkreliplanet For 30% Off The First Month Follow Martin Shkreli On Twitter: https://twitter.com/MartinShkreli Follow Martin Shkreli On Instagram: https://www.instagram.com/martinshkreli15/ Trade on Interactive Brokers: https://tinyurl.com/ye2aj6uz Book Recommendation About Stocks & Investing: Common Stocks and Uncommon Profits By Phil Fisher: https://amzn.to/3MCip3R The Intelligent Investor By Benjamin Graham: https://amzn.to/3Xn7jnY One Up On Wall Street By Peter Lynch: https://amzn.to/3XlrfYx
About Shkreli Planet
Shkreli Planet

Shkreli Planet

By @shkreliplanet